Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Proceedings of the American Thoracic Society 4:378-386 (2007)
© 2007 The American Thoracic Society
doi: 10.1513/pats.200703-039BR
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Related articles in Proceedings of the American Thoracic Society
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goss, C. H.
Right arrow Articles by Quittner, A. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goss, C. H.
Right arrow Articles by Quittner, A. L.

Patient-reported Outcomes in Cystic Fibrosis

Christopher H. Goss1 and Alexandra L. Quittner2

1 Department of Medicine, University of Washington Medical Center, Seattle, Washington; and 2 Department of Psychology and Pediatrics, University of Miami, Coral Gables, Florida

Correspondence and requests for reprints should be addressed to Christopher H. Goss, M.D., M.Sc., University of Washington Medical Center, Campus Box 356522, 1959 NE Pacific, Seattle, WA 98195. E-mail: goss{at}u.washington.edu

ABSTRACT

Over the past 20 years, there has been tremendous progress in the area of patient-reported outcomes (PROs). A PRO instrument is defined as any measure of a patient's health status that is elicited directly from the patient and assesses how the patient "feels or functions with respect to his or her health condition." The advances seen in clinical research regarding PROs has been mirrored in research in cystic fibrosis (CF). A large number of instruments have been used for both therapeutic and nontherapeutic clinical research for many chronic conditions. This review will summarize a history of the development of PROs and how PROs are viewed by the U.S. Food and Drug Administration. We will then review the current state of the art of patient-reported outcomes in CF, specifically addressing the evaluation of different PRO instruments in terms of their reliability and validity. Finally, we will delineate further areas for development of PROs in CF. We believe that the future of CF research will incorporate a more diverse selection of PRO outcome measures; these outcome measures ultimately may be incorporated into clinical care to standardize symptom assessment and provide information regarding the need for specific clinical interventions to improve the quality of care delivered to these patients.

Key Words: patient-reported outcomes • symptoms • quality of life • validity • instruments


Related articles in Proceedings of the American Thoracic Society:

Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Nicole Mayer-Hamblett, Bonnie W. Ramsey, and Richard A. Kronmal
Proceedings of the American Thoracic Society 2007 4: 370-377. [Abstract] [Full Text]  

Endpoints for Clinical Trials in Young Children with Cystic Fibrosis
Stephanie D. Davis, Alan S. Brody, Mary J. Emond, Lyndia C. Brumback, and Margaret Rosenfeld
Proceedings of the American Thoracic Society 2007 4: 418-430. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 ChestHome page
A. L. Quittner, A. C. Modi, C. Wainwright, K. Otto, J. Kirihara, and A. B. Montgomery
Determination of the Minimal Clinically Important Difference Scores for the Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Scale in Two Populations of Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Airway Infection
Chest, June 1, 2009; 135(6): 1610 - 1618.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Z. Retsch-Bogart, A. L. Quittner, R. L. Gibson, C. M. Oermann, K. S. McCoy, A. B. Montgomery, and P. J. Cooper
Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis
Chest, May 1, 2009; 135(5): 1223 - 1232.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
J Abbott
Health-related quality of life measurement in cystic fibrosis: advances and limitations
Chronic Respiratory Disease, February 1, 2009; 6(1): 31 - 41.
[Abstract] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. S. McCoy, A. L. Quittner, C. M. Oermann, R. L. Gibson, G. Z. Retsch-Bogart, and A. B. Montgomery
Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis
Am. J. Respir. Crit. Care Med., November 1, 2008; 178(9): 921 - 928.
[Abstract] [Full Text] [PDF]

Home page
 J Pediatr PsycholHome page
T. M. Palermo, A. C. Long, A. S. Lewandowski, D. Drotar, A. L. Quittner, and L. S. Walker
Evidence-based Assessment of Health-related Quality of Life and Functional Impairment in Pediatric Psychology
J. Pediatr. Psychol., October 1, 2008; 33(9): 983 - 996.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
B. W. Ramsey
Outcome Measures for Development of New Therapies in Cystic Fibrosis: Are We Making Progress and What Are the Next Steps?
Proceedings of the ATS, August 1, 2007; 4(4): 367 - 369.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Thoracic Society. 		 
Tobacco